T 1927/22 (PCSK9 inhibitor for reducing Lp(a)/REGENERON) of 06.12.2023
- European Case Law Identifier
- ECLI:EP:BA:2023:T192722.20231206
- Date of decision
- 6 December 2023
- Case number
- T 1927/22
- Petition for review of
- -
- Application number
- 12761864.3
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) for use in reducing lipoprotein(a) levels
- Applicant name
- Regeneron Pharmaceuticals, Inc.
- Opponent name
- Amgen Inc.
Boehmert & Boehmert Anwaltspartnerschaft mbB - Board
- 3.3.04
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 100(a)European Patent Convention Art 100(b)European Patent Convention Art 54European Patent Convention Art 56Rules of procedure of the Boards of Appeal 2020 Art 012(2)Rules of procedure of the Boards of Appeal 2020 Art 012(4)
- Keywords
- Novelty - main request (yes)
Amendment to case - argument
Amendment to case - reasons for submitting amendment in appeal proceedings (yes)
Sufficiency of disclosure - main request (yes)
Inventive step - main request (yes) - Catchword
- -
- Citing cases
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
1. The patent is maintained as granted.